Successful retransplantation of mouse-to-rat cardiac xenografts under immunosuppressive monotherapy with cyclosporine.
The present study was undertaken to investigate whether retransplantation with a second xenograft, from the same species as the primary graft, is possible to achieve using only moderate immunosuppression. Heterotopic mouse-to-rat cardiac transplantations were performed, and the recipients were treated with 15-deoxyspergualin (DSG) and cyclosporine (CsA) at high doses for days -1 to 4 and at moderate doses for days 5 to 28. From day 29 and onward, the immunosuppressive protocol consisted of daily oral administration of CsA 10 mg/kg as monotherapy. Animals that had beating grafts when DSG treatment was stopped were retransplanted 56-154 days after the primary transplantation, either with a vascularized graft (heart) or with nonvascularized graft (pancreatic islets), under continued therapy with CsA. Six of 10 secondary cardiac xenografts functioned for more than 50 days and were harvested beating after 60-100 days. In contrast, nonimmunosuppressed or DSG-treated rats are known to reject a second cardiac mouse graft hyperacutely. The unresponsiveness was confined to cardiac tissue, as the pancreatic islets, transplanted under the kidney capsule, were totally rejected after 14 days. Long-term functioning cardiac xenografts, primary and secondary, had a well-preserved morphology, and infiltrating mononuclear cells were found just in the periphery of the grafts. A majority of these cells were macrophages expressing the ED1, but not the ED2, antigen. No deposition of IgG or complement was seen in any of the graft vessels, whereas a slight deposition of IgM was observed in some vessels of both primary and secondary grafts. In conclusion, we have demonstrated that unresponsiveness can be induced by effective immunosuppression of the recipient at the time of the initial transplantation, so that retransplantation with a second xenograft can be performed successfully under single-drug immunosuppressive therapy with CsA.
Johnsson
C
C
Department of Transplantation Surgery, University Hospital, Uppsala, Sweden.
Andersson
A
A
Bersztel
A
A
Karlsson-Parra
A
A
Gannedahl
G
G
Tufveson
G
G
D000818:Animals; D016572:Cyclosporine / Q000627:therapeutic use*; D004727:Endothelium / Q000473:pathology; D019084:Fluorescent Antibody Technique, Indirect; D006146:Guanidines / Q000627:therapeutic use; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007328:Insulin / Q000032:analysis; D016381:Islets of Langerhans Transplantation / Q000276:immunology / Q000473:pathology; D051379:Mice; D051381:Rats; D011917:Rats, Inbred Lew; D012086:Reoperation; D014183:Transplantation, Heterologous / Q000276:immunology*
D006146:Guanidines; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D007328:Insulin; D016572:Cyclosporine; C037258:gusperimus